Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.

Abstract

No abstract available.

Authors
  • Arredouani MS
  • Dunn LK
  • Kissick HT
  • Sanda MG
PubMed ID
Appears In